Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445323 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
A Phase 1 study of Friedreich Ataxia and Cardiomyopathy, Secondary, sponsored by Lexeo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 3
- Study locations
NCT05445323 is a Phase 1 study of Friedreich Ataxia and Cardiomyopathy, Secondary that is active but no longer recruiting, run by Lexeo Therapeutics. The registered enrollment target is 8 participants, below the 449-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05445323, a Phase 1 study of Friedreich Ataxia and Cardiomyopathy, Secondary, is active but no longer recruiting, sponsored by Lexeo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post LX2006 treatment.
Conditions Studied
Interventions
- GENETIC Low dose LX2006
- GENETIC Mid Dose LX2006
- GENETIC High Dose LX2006
Study Locations (3)
California
- Ataxia Center and HD Center of Excellence, University of California - Los Angeles
Florida
- University of South Florida - Tampa
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05445323
The ClinicalTrials.gov registry entry for NCT05445323 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 449-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (98% lower). The listed sponsor is Lexeo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Friedreich Ataxia appearing as the primary indexed condition, and to 3 interventions - of which Low dose LX2006 is the first listed.
NCT05445323 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05445323 about?
NCT05445323 is a clinical study titled "Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia". This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated viru...
What is the current status of trial NCT05445323?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-08-24. Estimated completion is 2029-09.
What conditions does trial NCT05445323 study?
This clinical trial studies the following conditions: Friedreich Ataxia, Cardiomyopathy, Secondary.
What interventions are being tested in trial NCT05445323?
The interventions under investigation include: Low dose LX2006 (GENETIC), Mid Dose LX2006 (GENETIC), High Dose LX2006 (GENETIC).
Who is sponsoring clinical trial NCT05445323?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05445323 being conducted?
This trial has 3 study locations across California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Friedreich Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
RECRUITING · Phase 1
-
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
RECRUITING · Phase 1
-
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
COMPLETED · Phase 1
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
RECRUITING
-
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.